These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21325430)

  • 1. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
    Wang H; An N; Wang H; Gao Y; Liu D; Bian T; Zhu J; Chen C
    Drug Metab Dispos; 2011 May; 39(5):830-7. PubMed ID: 21325430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.
    Lee SJ; Kim WY; Kim H; Shon JH; Lee SS; Shin JG
    Drug Metab Dispos; 2009 Nov; 37(11):2262-9. PubMed ID: 19661214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae.
    Hanioka N; Tsuneto Y; Saito Y; Maekawa K; Sawada J; Narimatsu S
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):388-93. PubMed ID: 18312490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques.
    Uno Y; Matsushita A; Shukuya M; Matsumoto Y; Murayama N; Yamazaki H
    Biochem Pharmacol; 2014 Sep; 91(2):242-8. PubMed ID: 25036290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
    Shu Y; Wang LS; Xu ZH; He N; Xiao WM; Wang W; Huang SL; Zhou HH
    J Pharmacol Exp Ther; 2000 Nov; 295(2):844-51. PubMed ID: 11046127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.
    Sohn DR; Kwon JT; Kim HK; Ishizaki T
    Clin Pharmacol Ther; 1997 May; 61(5):574-82. PubMed ID: 9164419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
    Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
    J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24.
    Lau PS; Leong KV; Ong CE; Dong AN; Pan Y
    Biochem Genet; 2017 Feb; 55(1):48-62. PubMed ID: 27578295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
    Laine K; Tybring G; Bertilsson L
    Clin Pharmacol Ther; 2000 Aug; 68(2):151-9. PubMed ID: 10976546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.
    Griskevicius L; Yasar U; Sandberg M; Hidestrand M; Eliasson E; Tybring G; Hassan M; Dahl ML
    Eur J Clin Pharmacol; 2003 Jun; 59(2):103-9. PubMed ID: 12684728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.
    Goldstein JA; Faletto MB; Romkes-Sparks M; Sullivan T; Kitareewan S; Raucy JL; Lasker JM; Ghanayem BI
    Biochemistry; 1994 Feb; 33(7):1743-52. PubMed ID: 8110777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.
    Foti RS; Rock DA; Han X; Flowers RA; Wienkers LC; Wahlstrom JL
    J Med Chem; 2012 Feb; 55(3):1205-14. PubMed ID: 22239545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles.
    Foti RS; Wahlstrom JL
    Drug Metab Dispos; 2008 Mar; 36(3):523-8. PubMed ID: 18048485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
    Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA
    Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.